199 related articles for article (PubMed ID: 19846514)
1. Role of a putative gp41 dimerization domain in human immunodeficiency virus type 1 membrane fusion.
Liu J; Deng Y; Li Q; Dey AK; Moore JP; Lu M
J Virol; 2010 Jan; 84(1):201-9. PubMed ID: 19846514
[TBL] [Abstract][Full Text] [Related]
2. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
Cai L; Gochin M; Liu K
Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
[TBL] [Abstract][Full Text] [Related]
3. Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41.
Gustchina E; Bewley CA; Clore GM
J Virol; 2008 Oct; 82(20):10032-41. PubMed ID: 18667502
[TBL] [Abstract][Full Text] [Related]
4. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
5. Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41.
Gorny MK; Zolla-Pazner S
J Virol; 2000 Jul; 74(13):6186-92. PubMed ID: 10846104
[TBL] [Abstract][Full Text] [Related]
6. Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state.
Follis KE; Larson SJ; Lu M; Nunberg JH
J Virol; 2002 Jul; 76(14):7356-62. PubMed ID: 12072535
[TBL] [Abstract][Full Text] [Related]
7. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.
Finnegan CM; Berg W; Lewis GK; DeVico AL
J Virol; 2002 Dec; 76(23):12123-34. PubMed ID: 12414953
[TBL] [Abstract][Full Text] [Related]
8. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
Champagne K; Shishido A; Root MJ
J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
[TBL] [Abstract][Full Text] [Related]
9. Designing a soluble near full-length HIV-1 gp41 trimer.
Gao G; Wieczorek L; Peachman KK; Polonis VR; Alving CR; Rao M; Rao VB
J Biol Chem; 2013 Jan; 288(1):234-46. PubMed ID: 23184960
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
Keller PW; Morrison O; Vassell R; Weiss CD
J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
[TBL] [Abstract][Full Text] [Related]
11. Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex.
Welman M; Lemay G; Cohen EA
Virus Res; 2007 Mar; 124(1-2):103-12. PubMed ID: 17129629
[TBL] [Abstract][Full Text] [Related]
12. Structural and functional analysis of the HIV gp41 core containing an Ile573 to Thr substitution: implications for membrane fusion.
Liu J; Shu W; Fagan MB; Nunberg JH; Lu M
Biochemistry; 2001 Mar; 40(9):2797-807. PubMed ID: 11258890
[TBL] [Abstract][Full Text] [Related]
13. Interhelical interactions in the gp41 core: implications for activation of HIV-1 membrane fusion.
Wang S; York J; Shu W; Stoller MO; Nunberg JH; Lu M
Biochemistry; 2002 Jun; 41(23):7283-92. PubMed ID: 12044159
[TBL] [Abstract][Full Text] [Related]
14. Progress towards the development of a HIV-1 gp41-directed vaccine.
McGaughey GB; Barbato G; Bianchi E; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller MD; Pessi A; Shiver JW; Bogusky MJ
Curr HIV Res; 2004 Apr; 2(2):193-204. PubMed ID: 15078183
[TBL] [Abstract][Full Text] [Related]
15. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
Zhu Y; Ding X; Yu D; Chong H; He Y
J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design.
Joyce JG; Hurni WM; Bogusky MJ; Garsky VM; Liang X; Citron MP; Danzeisen RC; Miller MD; Shiver JW; Keller PM
J Biol Chem; 2002 Nov; 277(48):45811-20. PubMed ID: 12237296
[TBL] [Abstract][Full Text] [Related]
17. Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.
de Rosny E; Vassell R; Jiang S; Kunert R; Weiss CD
J Virol; 2004 Mar; 78(5):2627-31. PubMed ID: 14963170
[TBL] [Abstract][Full Text] [Related]
18. Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process.
Bär S; Alizon M
J Virol; 2004 Jan; 78(2):811-20. PubMed ID: 14694113
[TBL] [Abstract][Full Text] [Related]
19. Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.
Yuan C; Wang JY; Zhao HJ; Li Y; Li D; Ling H; Zhuang M
Retrovirology; 2019 Dec; 16(1):36. PubMed ID: 31796053
[TBL] [Abstract][Full Text] [Related]
20. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
